3 active not recruiting, 2 withdrawn, 1 recruiting. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Withdrawn 2 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Platinum-Resistant Fallopian Tube Carcinoma: new trials by email Literature Review of Recurrent Platinum-Resistant Fallopian Tube Carcinoma trials Research Report on Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab - Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 29 | 2018-02-01 | 2026-07-16 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-22 |
Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2)
Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
Magnetic Resonance Spectroscopy (4) · Disulfides (3) · Doxorubicin (3) · Immunoglobulin G (3) · Paclitaxel (3) · Specimen Handling (3) · Taxes (3) · liposomal doxorubicin (3) · Bevacizumab (2) · Topotecan (2) · olaparib (2) · ASTX-660 (1) · Bendamustine Hydrochloride (1) · Contrast Media (1) · Cyclophosphamide (1)
National Cancer Institute (NCI) (4) · City of Hope Medical Center (1) · Mayo Clinic (1)
United States (5) · Puerto Rico (2)
Brenda J. Ernst, M.D. (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Panagiotis A Konstantinopoulos (1) · Roisin E O'Cearbhaill (1) · Thanh Dellinger (1)
U10CA180868 (4), P30CA033572 (1)